Should rheumatologists prescribe statins?;Le rhumatologue doit-il prescrire des statines ?

Revue du Rhumatisme (Edition Francaise)

Volumn 77, Issue 2, 2010, Pages 115-117

  Soubrier, Martin ^a   Bruckert, Éric ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950574582     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2009.11.021     Document Type: Editorial

References (22)

1. Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (doi:10.1136/ard.2009.11396 ).
2. J.A. Avina-Zubieta, H.K. Choi, and M. Sadatsafavi Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies Arthritis Rheum 59 2008 1690 1697
3. M. Soubrier, S. Mathieu, and J.J. Dubost Atheroma and systemic lupus erythematosus Joint Bone Spine. 74 2007 566 570
4. A.E. Hak, E.W. Karlson, and D. Feskanich Systemic lupus erythematosus and the risk of cardiovascular disease: results from the Nurses' Health Study Arthritis Rheum 61 2009 1396 1402
5. D.J. Gordon, and B.M. Rifkind High-density lipoprotein-the clinical implications of recent studies N Engl J Med. 321 1989 1311 1316
6. M.H. Davidson, and P.P. Toth High-density lipoprotein metabolism: potential therapeutic targets Am J Cardiol. 100 11 A 2007 n32 40
7. B.H. Hahn, J. Grossman, and B.J. Ansell Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis Arthritis Res Ther. 10 2008 213
8. E. Choy, and N. Sattar Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions Ann Rheum Dis. 68 2009 460 469
9. C. Popa, L.J. van Tits, and P. Barrera Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients Ann Rheum Dis. 68 2009 868 872
10. J.M. McKenney Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks Am J Cardiol. 96 4A 2005 60E 66E
11. Agence franaise de sécurité sanitaire des produits de santé. Prise en charge thérapeutique du patient dyslipidémique. Mars 2005.
12. Anaes. Méthodes d'évaluation du risque cardiovasculaire global. Juin 2004.
13. M. Soubrier, D. Zerkak, and M. Dougados Indications for lowering LDL-c in rheumatoid arthritis: an unrecognized problem J Rheumatol. 33 2006 1766 1769
14. J. Wajed, Y. Ahmad, and P.N. Durrington Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management Rheumatology (Oxford). 43 2004 7 12
15. B.J. Ansell Targeting the anti-inflammatory effects of high-density lipoprotein Am J Cardiol. 100 11 A 2007 n3 9
16. C. Charles-Schoeman, D. Khanna, and D.E. Furst Effects of high-dose atorvastatin on anti-inflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study J Rheumatol. 34 2007 1459 1464
17. K.I. Paraskevas Statin treatment for rheumatoid arthritis: a promising novel indication Clin Rheumatol. 27 2008 281 287
18. D. McCarey, I. McInnes, and R. Madhok Trial of atorvastatin in rheumatoid arthritis (TARA): double blind, randomized placebo-control LES trial Lancet 363 2004 2015 2021
19. J.C. van Denderen, M.J. Peters, and V.P. van Halm Statin therapy might be beneficial for patients with ankylosing spondylitis Ann Rheum Dis. 65 2006 695 696
20. P.M. Ridker, and D.H. Solomon Should patients with rheumatoid arthritis receive statin therapy? Arthritis Rheum. 60 2009 1205 1209
21. E. Bruckert, G. Hayem, and S. Dejager Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study Cardiovasc Drugs Ther. 19 2005 403 414
22. S. Franc, S. Dejager, and E. Bruckert A comprehensive description of muscle symptoms associated with lipid-lowering drugs Cardiovasc Drugs Ther. 17 2003 459 465